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Early deaths and other challenges to childhood cancer survival in
Ibadan, Nigeria
*BJ BROWN, EA BAMGBOYE, O SODEINDE
Abstract
Objectives: To determine the frequency of early deaths and the associated risk factors in children suffering 
from cancer at the University College Hospital, Ibadan,
Design: A retrospective study involving review of case notes of children suffering from cancer.
Setting: Department of Paediatrics, University College Hospital, Ibadan, Nigeria.
Subjects: All cases of childhood cancer managed in the Department between January 1998 and December 
2004. Inclusion criteria were histological or cytological confirmation of diagnosis, suggestive clinical 
features and availability of details about the course of the illness
Main Outcome Measures: Interval between diagnosis and death, rate of early death (death within 30 days of 
diagnosis) and risk factors for early death.
Results: Eighty eight cases of childhood cancer were seen out of whom 52 died during the period Four cases 
with incomplete data were excluded from subsequent statistical analysis. There were 29 (34.5 %) early deaths 
defined as death within 30 days of diagnosis. The odds of early death were increased in the presence of 
bilateral kidney involvement, masses in the liver, splenic masses, pulmonary metastasis and stage D of 
Burkitt lymphoma. Logistic regression anaiysr revealed that pulmonary metastasis was a significant 
independent predictor o f early death.
Conclusions: Early childhood cancer mortality rate is high. Early diagnosis and referral for appropriate 
care may reduce childhood cancer modality in Nigeria.
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The ADOC regimen (Doxorubicin, Cisplatin, 
Vincristin and cyclophosphamide) for invasive 
malignant thymoma was used in the treatment of the 
only case of malignant thymoma.14
All children diagnosed and managed for cancer in 
the department between January 1998 and December 
2004 was studied. Inclusion criteria were histological 
or cytological diagnosis of tumour from aspirate or 
biopsy of tumour mass or bone marrow, radiological 
evidence of a malignant tumour in addition to 
suggestive clinical features and availability of details 
of clinical condition of the child at diagnosis and the 
clinical course of the illness.
Data Collection.
Data was extracted from the case notes and mortality 
summary cards of all the children diagnosed and 
managed for cancer the Department during the study 
period who met the inclusion criteria. The 
information extracted included age and sex of each 
case, the duration of the illness at presentation in the 
hospital, clinical stage of the disease, and organs 
affected at presentation. Information was also 
obtained on the course of the illness with respect to 
treatment, response to treatment and the time interval 
between diagnosis'and death.
Early death was defined as death within 30 days of 
diagnosis of the malignant condition 
and the date of diagnosis was the day on which the 
diagnostic test that confirmed the diagnosis was done 
e.g. the day on which fine needle aspiration biopsy or 
bone marrow aspirate was performed.1,6 For the 
purpose of uniformity and ease of comparability, 
clinical staging was done using the SEER 
(Surveillance, Epidemiology and End Results) 
clinical staging.15 In addition; cases of Burkitt's 
lymphoma were further staged according to the 
National Cancer Institute (NCI).16 Staging was done 
using at least clinical signs and diagnostic imaging 
(chest radiographs and abdominal ultrasonography), 
in all patients, and when necessary surgery and 
cytology. Reporting the results of cancer treatment 
response was based on World Health Organization 
guidelines.17
Data Analysis and Statistical Techniques.
Data analysis was done using the SPSS version 11.0. 
Means, medians and standard deviations were 
computed to summarize continuous variables and 
proportions and percentages for qualitative variables 
.The Student's t-test for independent samples was 
used to investigate the significance of two mean 
values while the chi-square test was used for the 
association of two categorical variables. Statistical 
significance was set at p<0.05. Risk factors of early 
death were analyzed by computing the odds ratio and 
95% confidence intervals using involvement of 
various organs at diagnosis as variables. Statistically 
significant risk factors were then subjected to logistic 
regression to determine independent predictors of
early death. The outcome variable was coded as 
either death within 30 days of diagnosis or death 
beyond 30 days. Cases that were discharged against 
medical advice in less than 30 days from diagnosis 
were excluded from the analysis of risk factors for 
early death. Diagnosis of cancer was made on each 
child at different points in time during the seven year 
period. Survival in terms of time between diagnosis 
and death was analyzed for all patients using the 
Kaplan-Meier method.18
Results
During the study period, 88 cases of childhood 
cancer were diagnosed at the Department of 
Paediatrics out of which there were 52 deaths. 
However, 4 cases of cancer mortality were excluded 
from the analysis due to lack of completeness of 
important data.
The ages of all the remaining 84 patients at diagnosis 
ranged from 1-13 years with a mean of 7.0 ± 3.2 and 
median of 7.0 years. Among all cancer cases seen, 
there were 62(73.8%) males and 22(26.2%) females 
giving a male: female ratio of 2.81: 1.0 
The distribution of the different tumour types seen 
in the 84 cancer patients studied is shown in Table I 
and reveals that Burkitt's lymphoma constituted the 
predominant tumour type followed by the leukaemias 
and Wilm's tumour.
Table I: Distribution o f tumor types in all cases o f 
cancer seen in the Department o f Paediatrics, UCH, 
Ibadan, 1998-2004.
Tumour type Frequency Percent












The duration of the illness at presentation in UCH 
ranged from 1 week to 52 weeks with a mean of 9.83 
± 9.33 weeks and median of 6 weeks.
Based on SEER stages 8(9.5%) of all cases had 
localized disease, 16(19.1%) had regionalized disease 
and 60 (71.4%) had diffuse or metastatic disease at 
diagnosis. Similarly, among the mortality cases, 
majority 40(83.3%) presented with metastatic
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Introduction
Early deaths (defined as death occurring within 30 
days of cancer diagnosis) could be an important 
indicator of the poor quality of cancer care often 
attributed to delayed diagnosis, rapid progression of 
disease or treatment related events such as 
chemotherapy toxicity and surgical complications.1'5 
However, risk factors for early deaths from childhood 
cancer have received limited attention in both clinical 
series and population based studies.
The population-based Childhood Cancer Registry 
of Piedmont (CCRP) Italy6 investigated the 
occurrence of early death in 3006 cases of childhood 
cancer diagnosed during the period 1967-1998. The 
proportion of children with cancer who died within 1 
month of diagnosis decreased from 10.8% in 1967- 
1978, to 5.3% in 1979-1988 and 1.8% in 1989-1998. 
This decreasing trend was attributed to early and 
improved diagnosis, more effective therapy or more 
frequent referral to specialized centres. Similarly, 
Hamre et al' reported a decrease in the proportion of 
early deaths associated with childhood cancer during 
the past 2 decades in the United States. This 
decreasing trend is adduced to earlier diagnosis or 
improved imaging capabilities, surgical techniques, 
medical therapy, and supportive care. Awareness of 
the need for early diagnosis and referral of childhood 
cancer with a focus on high-risk groups is therefore 
important in improving childhood cancer survival. 
Risk factors for early death observed by various 
workers include age <1 year, diffuse disease at 
diagnosis, a diagnosis of acute non-lymphocytic 
leukaemia, non-Hodgkin lymphoma, neuroblastoma, 
central nervous system tumour or hepatic tumour.1'6
Unfortunately, the matter of early deaths in cancer 
and its risk factors have received little attention in the 
developing world and indeed in Nigeria. The few 
available data on childhood cancer from Nigeria 
suggest a poor outcome with majority being dead or 
lost to follow up within a year of diagnosis.7'6 
Identification of risk factors for early deaths and 
other factors militating against survival from 
childhood cancer is therefore, important in 
developing appropriate strategies to improving 
survival. The objectives of this review were therefore 
to determine the frequency of early deaths and 
associated risk factors as well as identifying other 
challenges to survival in children suffering from 
cancer.
Methodology
The design was a retrospective study of children with 
cancer at the Department of Paediatrics of the 
University College Hospital (UCH) Ibadan, Nigeria. 
The UCH is an 850-bed tertiary institution located in 
Oyo state in the South- Western geopolitical zone of 
Nigeria. It receives referrals primarily from the state 
and suburbs but occasionally from various states in 
both the northern and southern parts of the country.
The care of children with cancer in this hospital 
involves a dedicated paediatric oncology specialist 
who continues to upgrade his knowledge and care of 
the patients. Radiotherapy is consistently available 
but due to high costs, sometimes not affordable by 
parents. Cytotoxic drugs are usually available for the 
various cancers seen in the hospital. During the study 
period Burkitt's lymphoma was treated with modified 
Ziegler's regimen designated as intravenous (i.v.) 
cyclophosphamide lg/m2 on day 1, i.v. vincristine 
1.5mg/m2 day 1, i.v. methotrexate 37.5mg/m2 on day 
1 or 12.5mg/m2 given orally on days 1-3 and oral 
prednisolone 40mg/m2 in 3 divided doses on days 1-
3. Subcutaneous cytosar 100mg/m2 per day given 
12hourly on days 1-3 could be given in place of
i.v.methotrexate. Intrathecal cytosar 50mg/m2 or 
methotrexate 12.5mg/m2 on days 1 and 5 were also 
given and the entire cycle repeated every 14 days up 
to a total of six cycles. Other Non-Hodgkin's 
lymphomas were treated with eight courses of 
standard 21day-CHOP regimen including 
cyclophosphamide 750mg/m2 i.v on day 1, 
doxorubicin 50mg/m2 i.v. on day 1, vincristine 
1.4mg/m2 on day 1 and prednisolone lOOmg daily for 
5days. The COAP regimen used for remission 
induction and consolidation of Acute lymphoblastic 
leukaemia consisted of i.v. cyclophosphamide, 
vincristine, subcutaneous cytosine arabinoside and 
oral prednisolone in a 28 day cycle.10 Intrathecal 
cytosine arabinoside was also given as central 
nervous system prophylaxis. Following complete 
remission, maintenance therapy consisted of oral 
methotrexate and 6-mercaptopurine. Acute myeloid 
leukemia (AML) was treated with doxorubicin, 
cytosine arabinoside and 6-thioguanine (DAT). 
However, due to the high cost and frequent 
unavailability of 6-thioguanine, COAP was more 
often used for the treatment of AML. Wilm's tumour 
chemotherapy was based on the conclusions of the 
National Wilms' Tumour Study program using 
various combinations of Vincristine, Actinomycin D, 
Doxorubicin and cyclophosphamide." Patients with 
rhabdomyosarcoma were treated based on the 
recommendations of the Intergroup 
Rhabdomyosarcoma Study IV (IRS IV) with 
combinations of cyclophosphamide, actinomycin D 
and cyclophosphamide (VAC) and radiotherapy.12 
One patient with hepatoblastoma was discharged 
against medical advice without treatment whilst the 
second with hepatoblastoma as well as the only 
patient with osteosarcoma were very ill at 
presentation and died before treatment could be 
started. The patient with retinoblastoma had 
localized disease and was treated with surgery and 
radiotherapy. The patients with Neuroblastoma were 
treated with the Dana-Farber Cancer Institute 
MADDOC protocol13 consisting of the use of 
Nitrogen Mustard, Adriamycin, DTIC, Cisplatin, 
Vincristin and cyclophosphamide but with exception 
that DTIC was omitted due to its non-availability.
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disease, 6(12.5%) presented with regionalized 
disease and only 2 (4.2%) had localized disease at 
diagnosis.
The outcome of all the patients studied is shown in 
Table II. Majority (57.1%) of the cases died while the 
remaining 42.9 % were lost to follow up at varying 
times ranging from before commencement of 
treatment to after completion of treatment. The main 
reason for default was discharge against medical 
advice due to financial difficulty followed by failure 
to return for treatment when allowed home on parole 
between courses of treatment.
Tabke II: Outcome o f 84 children with cancer.
Outcome No. Percent
Died 48 57.1
Default after completion of treatment 
Discharged on parole between
3 3.6
Treatment courses and defaulted 
Discharged against medical advice
13 15.5
for financial difficulty 
Discharged against medical advice
14 16.7
due to poor response 
Referred abroad for continuation
4 4.8
of therapy 2 2.4
Total 84 100.1
Out of all the cases, 64(76.2%) received treatment 
but only 11(13.2%) of all cases completed the 
required courses of treatment. Treatment consisted of 
surgery and chemotherapy in 1(1.6%), chemotherapy 
and radiotherapy in 2 (3.1%), chemotherapy and 
surgery in 5 (7.8%) and chemotherapy alone in 56 
(87.5%) of the treated children. Analysis of state of 
response when last seen showed that among 64 
children that were treated, 15(23.4%) had complete 
response out of which 12(18.8%) later had relapse 
whereas 20(31.3%) had partial response out of which 
2 (3.1%) later had disease progression. There was no 
response in 9(14.1%), disease progression in 5 
(7.8%) and response could not be assessed in the 
remaining 15(23.4%) patients because they either 
died or were discharged before four weeks of 
treatment. Among the 11 patienis who completed 
their required courses of treatment 6 had initial 
complete response with relapse later, 3 had partial 
response, 1 had partial response with disease 
progression later and 1 had disease progression in 
spite of treatment but second line drugs could no! be 
obtained locally.
Out of the 43 cases with Burkitt's lymphoma, only 
36 received chemotherapy and the rer . ning 7 either 
died before treatment could be comm ~ .ceu _ ere 
discharged from the hospital against medical advice. 
However, only 26 could be assessed for response to 
treatment as 10 patients died early and so response
could not be evaluated. Six (23.1%) of the 26 
evaluable patients had complete response, 17 (65.4%) 
had partial response and 3(11.5%) had no response. 
Twelve (70.6%) of the 17 patients with partial 
response had incomplete treatment due to financial 
constraints and defaulted from treatment.
Cancer Survival.
Survival from diagnosis to death ranged from 1 day 
to 208 weeks with a mean of 45.01 weeks and a 
standard error of 14.82 weeks. Median survival was 
10 weeks and the 26 week (6 month) survival 
estimate was 0.41 (Figure I).
Figure I: Survival function o f all cases o f cancer.
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At one year from diagnosis, cumulative survival was 
about 25%. There was no significant correlation 
between duration of illness at presentation in UCH 
and survival (£= 0.032, p=0.831) among mortality 
cases.
Early Deaths.
Out of the 84 cases analyzed there were 29 early 
deaths yielding an early death rate of 
34.5 %. Five patients were discharged against 
medical advice in less than 30 days from diagnosis 
and so were excluded from the analysis of risk 
factors of early death.
Table III shows the frequency of early death in 
different tumours and reveals that neuroblastoma and 
hepatoblastoma had higher frequencies of early death 
than others. Logistic regression analysis of all the 
underlying causes of death (tumeurs) however 
showed that nonc was a significant predictor of ea rly  
death.. Analysis of age groups (<! year, 1-4, 5-9 and 
10-14 years) also showed no significant association 
between age group at diagnosis and early death.
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Table III: Frequency of early deaths in different tumours.
Tumour type All casesf Early deaths
No. %
Burkitt’s lymphoma 39 15 38.5
Other Non-Hodgkin’s lymphomas 8 2 25.0
Leukaemias 9 . 4 44.4
Wilm’ tumor 10 3 30.0
Rhabdomyosarcoma 4 1 25.0
Neuroblastoma 3 2 66.7
Hepatoblastoma 2 1 50.0
Retinoblasma 1 0 0.0
Osteosarcoma 1 1 100
Thymoma 1 0 0.0
fExcluding those discharged against medical advice within 30 
days.
risk of early death (Table V). Although the early 
death rate among all the patients with Burkitt's 
lymphoma was 38.5 per cent, among the 36 patients 
who received treatment, 10 died early yielding an 
early death rate of 27.8 per cent.
Table V: Early deaths in different stages o f Burkitt s Lymphoma.
Stage All cases Early deaths 
No. %
p value
A 2 0 0 - -
B 3 0 0 - -
C 12 3 25.0 0.63 0.426
D 22 12 54.5 4.07 0.044
Risks factors for early death were assessed based 
on clinical stage (metastasis versus non-metastasis) 
and organ involvement at diagnosis and the results 
shown in Table IV.
Table IV: Stage and Organ involvement as risk factors for early 
death.
R isk  fa c to r E a r ly  d e a th
( n - 2 9 )
S u r v iv a l b e y o n d  
3 0  d a y s  (n « 4 9 )
A ll  c a se s
(n = 7 8 )
O R  (9 5 %  C l)
S ta g e
M etastasis 27 27 54 11.00(2 .35 ,51 .45)*
O rg a n s
C N S f 8 12 20 1 .1 8 (0 .4 1 ,3 .3 3 )
. 4 .29(1 .16 , 15.84)*Lungs 8 4 12
Live enlargem ent 17 22 39 1.74(0 .69 ,4 .40)
L iver m asses 10 5 15 4.63(1.39, 15.39)*
Splenic
Enlargem ent 14 18 32 1.61(0 .63 ,4 .08)
Intra-splenic
M asses 5 1 6 10 .0 (1 .11 ,90 .45)*
1 kidney 7 11 18 1.10(0.37, 3 .25)
Both kidneys 7 3 10 4.88(1 .15 ,20 .69)*
Testis 2 2 4 1.74(0.23, 13.07)
O varies 0 1 1 -
The risk of early death was increased in the 
presence of metastasis, involvement of the lungs and 
bilateral kidney involvement. Enlargement of the 
liver and spleen were associated with increased risk 
of early death only when there was gross radiological 
evidence of masses or infiltrates in them. Logistic 
regression analysis of organ involvement showed 
only pulmonary involvement to be a statistically 
significant independent predictor of early death (exp 
p= 4.45 [95% Cl = 1.07, 18.53]). Ovarian 
involvement was bilateral, occurred in only one 
patient and survival was beyond 30 days. Only one 
patient had bilateral testicular involvement and died 
early. Fifteen (51.7%) of the 29 cases of early death 
received no treatment before death either because 
they came in very sick and were being resuscitated or 
could not raise enough funds to start treatment early 
enough.
Analysis of the rate of early death in patients with 
the different NCI stages of Burkitt's lymphoma 
revealed that Stage D disease accounted for the 
majority of cases and was associated with increased
Discussion
The 34.5% rate of early deaths observed in this study 
is much higher than the rates reported by other 
workers that have ranged from 4.1% to 10.8 %.6'19 20 
It is however important to note that the latter reports 
are based on population-based cancer registries and 
therefore involved larger numbers of children 
registered over time periods sometimes up to three 
decades.6 Never- the- less the high early death rate 
observed in the present study is a cause for concern. 
Among the factors that might be responsible for the 
frequency of early deaths is presentation at a 
metastatic stage of the disease which was observed in 
over seventy percent of all cases and eighty per cent 
of all deaths in the present study. The increased risk 
of early death in patients with metastatic disease at 
diagnosis observed in our study has been previously 
reported by other workers.6 However; duration of 
illness at presentation did not significantly predict 
early deaths. This may be because although 
generally speaking the longer the delay in the 
duration of the illness, the more advanced the 
disease, Burkitt's lymphoma which contributed most 
to early deaths in our study is a rapidly proliferating 
tumor.21 It may therefore present as an advanced 
tumour within a very short time.
Presentation at stage D of Burkitt's lymphoma was 
also associated with an increased risk of early death 
in our study. This is in keeping with findings by 
Olweny el a f2 in Uganda where 88 percent of early 
deaths in Burkitt's lymphoma were patients in stages 
C and D.
Unfortunately, over half of our cases presented in 
stage D which is in consonance with recent findings 
by Fasola et a f  who observed 76.1% of Burkitt's 
lymphoma patients studied in Ibadan to be in stage D. 
The frequency of non-response in our patients with 
Burkitt's lymphoma was 11.5 % and similar to 11 % 
observed in Uganda. However, the rate of complete 
response in our patients was 23.1% and although 
similar to earlier findings in our institution of 22.8 %,
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it was low compared to 81 % observed in Uganda.22 
The early death rate observed in our study was also 
high compared with 33 out of 280 patients (11.8%) in 
the report from Uganda. The superior response 
achieved in the Ugandan children compared to ours 
was probably due to the fact that while the studies 
reported by Olweny et a f2 were all Clinical Trials in 
which patients would have had ready access to 
adequate chemotherapy and supportive care unlike 
our patients who were financed by their parents 
majority of whom could not afford the cost of drugs. 
Hence most of the patients who had partial response 
were unable to complete the course of chemotherapy 
required to achieve complete response. This accounts 
for the disparity in- complete response rates in spite of 
the similar non-response rates of patients in our study 
and those reported by Olweny et al.22
Lack of treatment also appreciably contributed to 
early deaths in our study. Qver 50% of the cases who 
died early received no treatment because they were 
very ill and were still being resuscitated and prepared 
for treatment when they died. These problems were 
probably due to late diagnosis and referral from 
primary and secondary health facilities to tertiary 
centres for treatment.
Previous studies have observed increased risk of 
early deaths in certain tumours compared to others. 
These include a diagnosis of neuroblastoma, central 
nervous system tumour, acute non-lymphocytic 
leukaemia and tumours in the liver.1'6 Our study 
similarly found higher early death rates in 
neuroblastoma and hepatoblastoma compared with 
other tumours. However, logistic regression analysis 
of the tumours in the present study failed to reveal 
increased risk in any of them probably due to the 
small numbers of cases of neuroblastoma and 
hepatoblastoma involved. An increased risk of death 
in infants with cancer has also been observed but no 
infants were seen in the present study and logistic 
regression analysis failed to reveal any age group to 
be at increased risk of early death.
In the present study, the odds for early death were 
increased in the presence of intra-hepatic masses. 
Other workers have similarly observed that children 
with liver tumours are at increased risk of early 
death.16 Other factors found to be associated with 
increased risk of early death in our study include 
splenic masses, pulmonary metastasis and 
involvement of both kidneys by the tumour. It is note 
worthy however that clinical enlargement of the liver 
and spleen without discrete masses or infiltrates 
within the respective organ was not associated with 
early death. Logistic regression showed only 
pulmonary metastasis to be a significant independent 
predictor of early death. . In view of these findings, 
management of patients with tumour involvement of 
the lungs, both kidneys and tumour inti’lin.*mn of the 
liver and spleen should include careful monitoring if 
possible in an intensive care unit to prevent early 
death.
Central nervous system disease was found not to be 
significantly associated with early death in this study 
unlike what was reported by Pastore et al,6 Hamre et 
al' and Creutzig et a l24 The difference in the findings 
between the latter studies and the present one may be 
due to differences in tumour types prevailing in the 
different environments involved. While Hamre and 
Pastore studied children in Italy and Hamre in the 
United States where primary central nervous system 
tumours are quite common and associated with a high 
risk of early death, the patients in the present study 
where mainly cases of Burkitt's lymphoma with 
involvement of the central nervous system It is 
therefore probable that primary central nervous 
system tumours are more aggressive than Burkitt's 
lymphoma in causing early mortality.
The findings of the present study suggest poor 
survival from cancer although the results were 
however limited by a high rate of loss to follow up 
and incomplete treatment. It is however of interest to 
observe that the obtained values are in keeping with 
previous reports of poor survival from childhood 
cancers in Nigeria. Recently, Kagu et a l25 reported a 
mean survival of 10.5 + 3.4 weeks in children who 
died of Burkitt's lymphoma and a 5-year survival of 
only 1.9%. Other previous reports from Nigeria have 
also revealed a poor outcome with death of most of 
the children in less than a year of diagnosis.7’9 These 
studies have however been characterized by high 
rates of default and such cases often assumed to have 
died. This actually makes it difficult to obtain the 
accurate survival rates in Nigeria. The present study 
is similarly limited by the fact that it is based on 
hospital records and almost 43% of the patients 
defaulted from treatment mainly due to financial 
constraints. Another major reason for default was the 
opportunity of going home on parole following some 
response to treatment and this poses a major 
challenge bearing in mind the often protracted 
duration of cancer treatment making it unrealistic for 
a child to remain on admission throughout the length 
of therapy. An interplay of the latter two factors 
resulted in the poor response to therapy observed in 
our study.
The matter of discharge against medical advice 
observed in the present study is a major challenge in 
management of childhood cancer in Nigeria and has 
been previously reported by Fasola et al23 in Ibadan. 
Our study has shown that in addition to financial 
difficulty being the major reason as reported by 
Fasola et al2’, some other parents ask for discharge of 
their children due to poor response to first line 
therapy making them to resort to alternate therapy by 
traditional healers. In addition to efforts at correcting 
this attitude which is due to ignorance, there is also 
need to make concerted efforts to provide second line 
cytotoxic drugs which are usually hard to find in the 
country and occasionally have to be ordered from 
abroad by a few wealthy parents.
Cent Afr JM ed 2008;54(5/8) 37
Conclusion
This study has shown that survival from childhood 
cancer at the Paediatrics Department of the 
University College Hospital Ibadan for the period 
under review was poor with a zero 5-year survivor; 
the median survival was 10 weeks and the patient who 
lived longest died 208 weeks (4 years) after 
diagnosis. Most patients presented with advanced 
disease with a resultant high rate of early death often 
before or shortly after commencement of treatment. 
Risk factors for early death include the presence of 
intra-hepatic masses, intra-splenic masses, and 
bilateral kidney involvement by tumour and 
pulmonary metastasis the latter being an independent 
predictor of early death. Other challenges to survival 
include a high rate of loss to follow up, discharge 
from treatment against medical advice and financial 
constraints to completion of therapy. Health 
education of the public and sensitization of medical 
practitioners on the need for early presentation at the 
hospital, prompt referral as well as free or 
significantly subsidized treatment for cancer could 
have a significant impact on childhood cancer 
survival in Nigeria. Careful evaluation of all children 
with cancer to identify risk factors for early death 
utilizing routine chest X-rays and abdominal 
ultrasound scans among other measures and prompt 
anticipatory management may also reduce the 
frequency of early deaths and improve survival. 
Population-based cancer registries should be 
established across the country to in addition to 
keeping record of all cancer cases also monitor and 
record survival and deaths in order to accurately 
quantify the incidence and survival of childhood 
cancer.
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